Abstract:Objective: While the molecular events controlling insulin secretion from β-cells have been documented in detail, the exact mechanisms governing glucagon release by α-cells are understood only partially. This is a critical knowledge gap, as the normal suppression of glucagon secretion by elevated glucose levels fails in type 2 diabetes (T2D) patients, contributing to hyperglycemia through stimulation of hepatic glucose production. A critical role of glycolytic flux in regulating glucagon secretion was supported by recent studies in which manipulation of the activity and expression of the glycolytic enzyme glucokinase altered the setpoint for glucose-suppression of glucagon secretion (GSGS). Given this precedent, we hypothesized that genetic activation of glucokinase specifically in α-cells would enhance GSGS and mitigate T2D hyperglucagonemia. Methods: We derived an inducible, α-cell-specific glucokinase activating mutant mouse model (GckLoxPGck∗/LoxPGck∗; Gcg-CreERT2; henceforth referred to as "α-mutGCK") in which the wild-type glucokinase gene (GCK) is conditionally replaced with a glucokinase mutant allele containing the ins454A activating mutation (Gck∗), a mutation that increases the affinity of glucokinase for glucose by almost 7-fold. The effects of α-cell GCK activation on glucose homeostasis, hormone secretion, islet morphology, and islet numbers were assessed using both in vivo and ex vivo assays. Additionally, the effect of α-cell GCK activation on GSGS was investigated under diabetogenic conditions of high-fat diet (HFD) feeding that dysregulate glucagon secretion. Results: Our study shows that α-mutGCK mice have enhanced GSGS in vivo and ex vivo, independent of alterations in insulin levels and secretion, islet hormone content, islet morphology, or islet number. α-mutGCK mice maintained on HFD displayed improvements in glucagonemia compared to controls, which developed the expected obesity, glucose intolerance, elevated fasting blood glucose, hyperinsulinemia, and hyperglucagonemia. Conclusions: Using our novel α-cell specific activation of GCK mouse model, we have provided additional support to demonstrate that the glycolytic enzyme glucokinase is a key determinant in glucose sensing within α-cells to regulate glucagon secretion. Our results contribute to our fundamental understanding of α-cell biology by providing greater insight into the regulation of glucagon secretion through α-cell intrinsic mechanisms via glucokinase. Furthermore, our HFD results underscore the potential of glucokinase as a druggable target which, given the ongoing development of allosteric glucokinase activators (GKAs) for T2D treatment, could help mitigate hyperglucagonemia and potentially improve blood glucose homeostasis.

Generation of permanent neonatal diabetes mellitus dogs with glucokinase point mutations through base editing

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

Permanent Neonatal Diabetes Mellitus in China

Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Reversal of Streptozotocin-Induced Diabetes in Rats by Gene Therapy with Betacellulin and Pancreatic Duodenal Homeobox-1

Neonatal diabetes mellitus around the world: Update 2024

Prime editor-mediated correction of a pathogenic mutation in purebred dogs

Permanent Neonatal diabetes-causing Insulin mutations have dominant negative effects on beta cell identity

Nanoparticle‐mediated genome editing in single‐cell embryos via peptide nucleic acids

Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein

Precision medicine in diabetes: A non-invasive prenatal diagnostic test for the determination of fetal glucokinase mutations

Precision modeling of mitochondrial disease in rats via DdCBE-mediated mtDNA editing

Establishment of Liver Specific Glucokinase Gene Knockout Mice: a New Animal Model for Screening Anti-Diabetic Drugs.

Case report: A 10-year prognosis of neonatal diabetes caused by a novel INS gene mutation

Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis

Genetically humanized phenylketonuria mouse model as a testing tool for human genome editing in fertilized eggs

Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states